AR and Familial prostate cancer: Targeting activities of the androgen receptor (AR) by depriving it of androgen is a key therapeutic approach for prostate cancer; however, resistant tumors eventually occur and can progress to metastatic castration-resistant prostate cancer (CRPC) [1].